Holen Sie sich die Stockscreener-App
91.69
1.27%
1.15
Handel nachbörslich:
91.69
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca plc Stock Is Quietly Going Off — Is This Your Next Power Move? - AD HOC NEWS
Is This Dividend King Stock a Buy After a Major Development? - The Motley Fool
Migdal Insurance & Financial Holdings Ltd. Acquires Shares of 194,000 AstraZeneca PLC $AZN - MarketBeat
Prediction: Analysts think the AstraZeneca share price will do this in 2026 - MSN
Eyes on Asia: AirNexis, AstraZeneca, Syngene International - BioXconomy
Astrazeneca expands China cell therapy footprint with Abelzeta CAR T - BioWorld MedTech
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates - TechStock²
AstraZeneca to delist from Nasdaq, join NYSE in February - Reuters
Why Is AstraZeneca Stock Trading Lower Today?AstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Shifts Listing from Nasdaq to NYSE - GuruFocus
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January - Investing.com
Dynasty Wealth Management LLC Invests $3.27 Million in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to complete direct listing in NY on February 2 - marketscreener.com
AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial - Finviz
AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate - Chartmill
AstraZeneca (AZN) to Consolidate Stock Listings on NYSE - GuruFocus
AstraZeneca To Move Nasdaq Listing To NYSE - DirectorsTalk Interviews
AstraZeneca Plans NYSE Listing for Shares, US Debt - Mirage News
AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange - AstraZeneca
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treat - GuruFocus
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus - TechStock²
AstraZeneca's Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Finviz
AstraZeneca’s Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Yahoo Finance
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy - Yahoo Finance
Prediction: analysts think the AstraZeneca share price will do this in 2026 - Yahoo Finance UK
AbelZeta and AstraZeneca Reach $630 Million Acquisition Agreement - Intellectia AI
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
AstraZeneca PLC $AZN Shares Sold by QRG Capital Management Inc. - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
AstraZeneca PLC agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million. - marketscreener.com
Trend Review: Does AstraZeneca PLC Depositary Receipt have a sustainable dividendEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
AstraZeneca share price steadies after Thursday drop as traders eye Nasdaq-100 reshuffle - TechStock²
Klein Pavlis & Peasley Financial Inc. Acquires New Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Cell Therapy Manufacturing Facility, Maryland, USA - Pharmaceutical Technology
AstraZeneca (AZN) Weighs FDA Fast-Track Risks Amid Legal Concerns - GuruFocus
Deutsche Bank Maintains ASTRAZENECA PLC(AZNCF.US) With Sell Rating, Raises Target Price to $147.24 - Futubull
AZN Stock Price, Forecast & Analysis | ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) - Chartmill
AstraZeneca (AZN) Acquires Modella AI to Boost Cancer Research - GuruFocus
AstraZeneca Acquires Modella AI to Accelerate Cancer Therapy Development - Intellectia AI
JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN) - MarketBeat
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
What Makes AstraZeneca (AZN) a Strong Growing Company? - Insider Monkey
AstraZeneca Spotlights 2025 Growth, 2026 Launch Wave and $80B 2030 Goal at JPM Conference - Yahoo Finance
Rep. Julia Letlow Buys AstraZeneca PLC (NASDAQ:AZN) Shares - MarketBeat
AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition - Pharmaceutical Technology
Manning & Napier Advisors LLC Sells 390,342 Shares of AstraZeneca PLC $AZN - MarketBeat
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale - marketscreener.com
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's Why - MarketBeat
Market Overview: Whats AstraZeneca PLC Depositary Receipts historical returnMarket Performance Recap & Intraday High Probability Alerts - baoquankhu1.vn
AstraZeneca: acquires Modella AI to strengthen its oncology research - marketscreener.com
AstraZeneca stock rating reiterated at Buy by Guggenheim ahead of Q4 results - Investing.com UK
AstraZeneca Buys US-based Modella AI - marketscreener.com
AstraZeneca CFO on M&A Strategy and Obesity Market - marketscreener.com
AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe - GuruFocus
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):